Proof of Concept Study on BP1.4979 Effect on Primary Premature Ejaculation

Recruiting Phase 2 Interventional Study
Premature (Early) Ejaculation
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 50
Sex
Male
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
60 (estimated)
Sponsor
Bioprojet · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this clinical trial is to learn if drug BP1.4979 works to treat primary premature ejaculation in adults. It will also learn about the safety of drug BP1.4979. The main questions it aims to answer are: * Does drug BP1.4979 increase the time to ejaculation during sexual intercourse? * Do participants have a good safety and tolerability of drug BP1.4979? Researchers will compare drug BP1…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Males aged 18 to 50 years old (both inclusive) * Diagnosis of primary (lifelong) PE according to the investigator * Intravaginal Ejaculatory Latency Time (IELT) estimated by the patient around one (1) minute at screening * Confirmation at randomization visit that at least 3 ti…
Contacts

Medical monitor, MD

+33 1 47 03 66 33

l.feldmann@bioprojet.com

CONTACT

Clinical Project Manager

+33 1 47 03 66 33

s.renaux@bioprojet.com

CONTACT